{"filing":{"accession_number":"0001193125-26-264043","cik":"0001579428","ticker":"AXSM","company_name":"Axsome Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-09","report_date":null,"primary_document":"axsm-20260605.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1579428/000119312526264043/axsm-20260605.htm"},"events":[{"id":5938,"run_id":5211,"accession_number":"0001193125-26-264043","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure reporting the results of Axsome's 2026 Annual Meeting of Stockholders held on June 5, 2026. The filing presents voting outcomes for three proposals: election of two Class II directors (Mark Saad and Susan Mahony, Ph.D., MBA), ratification of Deloitte \u0026 Touche LLP as independent auditor, and non-binding advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material shareholder governance event.","company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","filing_date":"2026-06-09","form":"8-K","submitted_at":null,"items":[{"id":5647,"accession_number":"0001193125-26-264043","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Axsome's 2026 Annual Meeting of Stockholders held on June 5, 2026. The filing presents voting outcomes for three proposals: election of two Class II directors (Mark Saad and Susan Mahony, Ph.D., MBA), ratification of Deloitte \u0026 Touche LLP as independent auditor, and non-binding advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material shareholder governance event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T21:21:06.686011+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5647,"accession_number":"0001193125-26-264043","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Axsome's 2026 Annual Meeting of Stockholders held on June 5, 2026. The filing presents voting outcomes for three proposals: election of two Class II directors (Mark Saad and Susan Mahony, Ph.D., MBA), ratification of Deloitte \u0026 Touche LLP as independent auditor, and non-binding advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material shareholder governance event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T21:21:06.686011+00:00","company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","filing_date":"2026-06-09"}]}